家族性慢性淋巴细胞白血病预后较散发性更差:一项意大利病例对照研究
这项多中心病例对照研究纳入意大利18个中心的480例成人慢性淋巴细胞白血病(CLL)患者,其中家族性CLL 160例、散发性CLL 320例,按性别和诊断年龄(±4年)1:2匹配。家族性CLL在诊断时淋巴结肿大>5 cm比例更高、免疫球蛋白重链可变基因未突变比例更高,一线和二线治疗需求更高,至首次治疗时间和至下次治疗时间更短,但总生存无差异。
要点
- 家族性CLL占CLL的5%–7%,本研究纳入160例家族性CLL和320例散发性CLL。
- 家族性CLL诊断时淋巴结肿大>5 cm比例7.2% vs 散发性2.8%(P=.027)。
- 家族性CLL免疫球蛋白重链可变基因未突变55.5% vs 散发性36.2%(P<.001)。
核心结论
- 家族性CLL较散发性CLL临床过程更具侵袭性,但总生存无差异。
- 鉴于家族性CLL更具侵袭性但总生存相似,作者认为不建议对CLL患者亲属进行CLL筛查。
研究设计与样本
- 多中心病例对照研究,纳入意大利18个中心的成人CLL患者。
- 家族性CLL定义为至少有1名一级亲属患CLL。
- 散发性CLL按生物学性别和诊断年龄±4年以1:2比例匹配。
- 共纳入480例患者,其中家族性CLL 160例、散发性CLL 320例。
- 采用Kaplan-Meier法评估至事件结局。
主要发现
- 诊断时淋巴结肿大>5 cm:家族性CLL 7.2% vs 散发性CLL 2.8%(P=.027)。
- 免疫球蛋白重链可变基因未突变:家族性CLL 55.5% vs 散发性CLL 36.2%(P<.001)。
- 一线治疗需求:家族性CLL 55.6% vs 散发性CLL 43.1%(P=.001)。
- 二线治疗需求:家族性CLL 46.1% vs 散发性CLL 29.6%(P=.034)。
- 中位至首次治疗:家族性CLL 66个月 vs 散发性CLL 108个月(P=.005);中位至下次治疗:家族性CLL 60个月 vs 散发性CLL 94个月(P=.030)。
关键数值与推荐
- 家族性CLL占CLL的5%–7%。
- 家族性CLL定义:至少有1名一级亲属患CLL。
- 匹配条件:按生物学性别和诊断年龄±4年,1:2比例。
临床怎么用
- 作者认为,鉴于家族性CLL更具侵袭性但总生存相似,不建议对CLL患者亲属进行CLL筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Familial chronic lymphocytic leukemia (CLL) constitutes 5% to 7% of CLL and has previously shown a more aggressive pattern of evolution than sporadic CLL, even if no difference in overall survival (OS) has been observed. This multicenter case-control study aimed to compare clinical features, molecular biomarkers, and patient outcomes of familial and sporadic CLL. Adult patients with CLL were enrolled from 18 Italian centers, with familial CLL defined as having at least 1 first-degree relative affected by CLL. Patients with sporadic CLL were matched for biological sex and age at diagnosis within 4 years (1:2 ratio). The Kaplan-Meier method was used to evaluate time-to-event outcomes. Of 480 enrolled patients, 160 had familial CLL and 320 sporadic CLL. Significant clinical and molecular differences between familial and sporadic CLL included the presence of lymphadenopathies at diagnosis >5 cm (7.2% vs 2.8%; P = .027) and unmutated immunoglobulin heavy chain variable gene (55.5% vs 36.2%; P < .001). First- and second-line treatments were required in 55.6% and 46.1% of familial CLL and 43.1% (P = .001) and 29.6% of sporadic CLL (P = .034), respectively. Both time to first treatment (TTFT) and time to next treatment (TTNT) were shorter for familial CLL than for sporadic CLL (median TTFT, 66 months vs 108 months; P = .005; median TTNT, 60 months vs 94 months; P = .030, respectively), although familiarity has not emerged as an independent prognostic factor. No difference in OS was observed. Considering the more aggressive course of familial CLL but similar OS, CLL screening in relatives is not recommended.
引用
- Fresa A, Innocenti I, Tomasso A, et al. Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study. Blood Adv. 2025. PMID: 40505061. doi:10.1182/bloodadvances.2025016546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。